Elsevier

Clinical Biochemistry

Volume 47, Issue 6, April 2014, Pages 327-337
Clinical Biochemistry

Review
Cardiac biomarkers in heart failure

https://doi.org/10.1016/j.clinbiochem.2014.01.032Get rights and content

Highlights

  • Heart failure is a growing health issue worldwide

  • This review focuses on current clinically available biomarkers.

  • The clinical characteristics and applications of each biomarker are discussed.

  • Biomarkers will play an increasing role in heart failure management in the future.

Abstract

Background

Heart failure is a syndrome characterized by the inability of the heart to meet the body's circulatory demands. Heart failure is a growing health issue worldwide and the prevalence of heart failure is expected to rise as populations age. Therapies and interventions for a variety of cardiac conditions continue to advance and biomarkers will play an increasing role in patient management.

Methods

This is a review of the clinical research in blood based biomarkers for diagnosis, prognosis and therapeutic guidance of heart failure. The focus of this review is biomarkers that are currently available for clinical measurement, and their current and potential for applications for managing heart failure patients.

Results

The various biologic pathways and physiologic processes of heart failure biomarkers represent a host of different including inflammation, remodeling, strain, neurohormonal activation, metabolism and cardiac myocyte injury. The clinical characteristics and applications of each heart failure biomarker are discussed.

Conclusion

As populations age and effective treatments and interventions for coronary artery disease improve, heart failure will increase in incidence and prevalence. Blood biomarkers will play an increasing role in the early diagnosis, therapeutic monitoring and management of heart failure patients in the future.

Introduction

Heart failure (HF) is a syndrome characterized by the inability of the heart to meet the circulatory demands of the body leading to many symptoms including dyspnea and fatigue. HF can arise from a host of conditions involving the myocardium or heart valves. HF occurs in about equal frequency with and without a reduced ventricular ejection fraction (EF). Each of these categories accounts for approximately 50% of all cases [1]. Regardless of category, HF is staged according to the American College of Cardiology/American Heart Association guidelines (Table 1) [2]. Additionally, a patient's functional status can be classified according to the New York Heart Association classification (Table 1) [2]. As can be seen from Table 1, there is overlap between HF stage and NYHA classification of symptoms.

HF is a burgeoning health and healthcare problem. There are an estimated 20 million affected individuals worldwide [3], of which 5.7 million are in the United States [4]. HF accounts for over one million hospitalizations in the United States, over three million physician office visits, and nearly 57,000 deaths annually [4]. In Canada hospitalizations for heart failure were reported as more than 106,000 annually [5]. The prevalence of HF is expected to continue to rise as early detection therapies for myocardial infarction (MI), valvular diseases and arrhythmias improve, thereby allowing patients to survive longer [3].

Despite its high prevalence, the diagnosis of HF remains difficult as none of the signs and symptoms are specific or particularly sensitive. Due to this, history and physical examination may not be sufficient to reach the diagnosis. Traditional adjuncts to diagnosis include echocardiography, stress testing, and various forms of radionuclide imaging. Each of these has their short-comings and for this reason, diagnostic aids in the form of blood-based biomarkers have been sought. Much research for the past decade has examined numerous possible biomarkers and in general these biomarkers can be broken down into six categories: markers of inflammation; extracellular matrix turnover and remodeling markers; markers of biochemical strain; markers of neurhormonal activation; markers of nutrition and metabolism; and markers of cardiomyocyte injury (Table 2). Given the large number of candidates, a systematic manner of assessing biomarkers and identifying those most likely to be relevant was needed. In 2007 Morrow and de Lemos [6] put forth three criteria for the evaluation of new biomarkers: first, the marker must be able to be measured reliably, quickly, and at reasonable cost; second, the marker must provide additional information that the physician cannot obtain from a historical and physical examination; and third, the marker must influence clinical decision-making.

Few biomarkers have successfully fulfilled each of these criteria. However, there are several promising targets. In this review, we will focus on markers that are either available for utilization by clinicians or have at least been evaluated rigorously in multiple research studies.

Section snippets

Markers of inflammation

Inflammation is now widely accepted as a component of the pathogenesis and progression of HF. This, however, has not always been the case. Initially, attempts were made to explain HF from a purely hemodynamic perspective. This “hemodynamic hypothesis” was unable to adequately explain the progression of HF so alternative explanations were sought. In 1996, Seta et al. put forth the “cytokine hypothesis.”[7] In this, they suggested that the progression of HF is, at least in part, explained by the

Procollagen

Collagen scar formation has been found to play an important role in the remodeling of cardiac tissue following MI and in the development of HF. For this reason markers of collagen synthesis and turnover have been studied as a non-invasive methodology to determine the extent of cardiac fibrosis.

Procollagen type III amino-terminal propeptide (PIIINP), a marker of collagen synthesis, is one of the most studied fibrosis markers. In the setting of acute MI, PIIINP has been shown to be elevated in

Natriuretic peptides

The natriuretic peptides are a group of neurohormones which affect body fluid homeostasis via natriuresis and diuresis [69]. The natriuretic peptides also decrease vasoconstriction by decreasing angiotensin II and norepinephrine synthesis [69]. There are two main types of natriuretic peptides: BNP and A-type natriuretic peptide (ANP). The most extensively studied of these peptides is BNP.

BNP is synthesized as a pre-prohormone and is released in response to volume overload and wall stress [89]

Copeptin

Arginine vasopressin (vasopressin; antidiuretic hormone; AVP; ADH) is a peptide hormone synthesized in the hypothalamus and stored in the posterior pituitary gland. ADH is known to have both antidiuretic and vasoconstrictive properties. Levels of ADH have been shown to be elevated in patients with HF [113], [114]. The excess ADH can lead to hyponatremia, fluid accumulation, and systemic vasoconstriction. Unfortunately, it is difficult to measure ADH levels as a large proportion of the hormone

Cardiac troponins

There are several markers of cardiomyocyte injury including the cardiac troponins, heart fatty acid binding protein, creatinine kinase MB and myosin light chain 1. As the troponins are currently the most clinically relevant they will be the focus of this section. The cardiac troponins are cardiac isoforms of proteins from the troponin-tropomyosin complex found in cardiomyocytes and there are two main types: cardiac troponin T (cTnT) and cardiac troponin I (cTnI). These proteins are known to be

Conclusion

During the last decade extensive research has been conducted in biomarkers and HF. While BNP and the cardiac troponins are ubiquitous in clinical practice, there are a host of other promising biomarkers which have the potential to be diagnostic, prognostic, and therapeutic aids extending from an asymptomatic general population to those hospitalized with acute HF. It is unlikely that any single one of the markers will prove to be the sole necessary aid in all HF settings. As data continues to

References (151)

  • V. Rudolph et al.

    Activation of polymorphonuclear neutrophils in patients with impaired left ventricular function

    Free Radic Biol Med

    (2007)
  • W.H.W. Tang et al.

    Plasma myeloperoxidase levels in patients with chronic heart failure

    Am J Cardiol

    (2006)
  • W.H.W. Tang et al.

    Prognostic value and echocardiographic determinants of plasma myeloperoxidase levels in chronic heart failure

    J Am Coll Cardiol

    (2007)
  • M. Elahi et al.

    NO-cGMP and TNF-α counter regulatory system in blood: Understanding the mechanisms leading to myocardial dysfunction and failure

    Biochim Biophys Acta (BBA) - Mol Basis Dis

    (2007)
  • S.D. Anker et al.

    How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH

    Int J Cardiol

    (2002)
  • M. Cicoira et al.

    Independent and additional prognostic value of aminoterminal propeptide of type III procollagen circulating levels in patients with chronic heart failure

    J Card Fail

    (2004)
  • T.J. Wang et al.

    Clinical and echocardiographic correlates of plasma procollagen type III amino-terminal peptide levels in the community

    Am Heart J

    (2007)
  • R.R. van Kimmenade et al.

    Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure

    J Am Coll Cardiol

    (2006)
  • H. Milting et al.

    Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices

    J Heart Lung Transplant

    (2008)
  • W.H.W. Tang et al.

    Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival

    Am J Cardiol

    (2011)
  • T. Ueland et al.

    Galectin-3 in heart failure: high levels are associated with all-cause mortality

    Int J Cardiol

    (2011)
  • R.A.P. Weir et al.

    Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction

    J Am Coll Cardiol

    (2010)
  • J.L. Januzzi et al.

    Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study

    J Am Coll Cardiol

    (2007)
  • S. Boisot et al.

    Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure

    J Card Fail

    (2008)
  • D.A. Pascual-Figal et al.

    Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction

    J Am Coll Cardiol

    (2009)
  • J. George et al.

    Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure

    Am Heart J

    (2005)
  • S. Buralli et al.

    Circulating matrix metalloproteinase-3 and metalloproteinase-9 and tissue Doppler measures of diastolic dysfunction to risk stratify patients with systolic heart failure

    Am J Cardiol

    (2010)
  • L.B. Daniels et al.

    Natriuretic peptides

    J Am Coll Cardiol

    (2007)
  • J.L. Januzzi et al.

    The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency department (PRIDE) study

    Am J Cardiol

    (2005)
  • J.G. Lainchbury et al.

    Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath

    J Am Coll Cardiol

    (2003)
  • R.R.J. van Kimmenade et al.

    Amino-terminal pro-brain natriuretic peptide, renal function, and outcomes in acute heart failure: redefining the cardiorenal interaction?

    J Am Coll Cardiol

    (2006)
  • G.C. Fonarow et al.

    Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure

    J Am Coll Cardiol

    (2007)
  • D. Logeart et al.

    Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure

    J Am Coll Cardiol

    (2004)
  • R.W. Troughton et al.

    Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations

    Lancet

    (2000)
  • T.E. Owan et al.

    Trends in prevalence and outcome of heart failure with preserved ejection fraction

    N Engl J Med

    (2006)
  • D.L. Mann et al.

    Heart failure and cor pulmonale

  • V.L. Roger et al.

    Heart Disease and Stroke Statistics—2012 update: a report from the American Heart Association

    Circulation

    (2012)
  • R.T. Tsuyuki et al.

    Contemporary burden of illness of congestive heart failure in Canada

    Can J Cardiol

    (2003)
  • D.A. Morrow et al.

    Benchmarks for the assessment of novel cardiovascular biomarkers

    Circulation

    (2007)
  • P.M. Ridker

    Clinical application of C-reactive protein for cardiovascular disease detection and prevention

    Circulation

    (2003)
  • M.S. Sabatine et al.

    Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease

    Circulation

    (2007)
  • B.M. Scirica et al.

    for the Thrombolysis in Myocardial Infarction (TIMI) Study Group. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes

    Clin Chem

    (2007)
  • J.L. Alonso-Martínez et al.

    C-reactive protein as a predictor of improvement and readmission in heart failure

    Eur J Heart Fail

    (2002)
  • E.S. Williams et al.

    C-reactive protein, diastolic dysfunction, and risk of heart failure in patients with coronary disease: Heart and Soul Study

    Eur J Heart Fail

    (2008)
  • D.J. Campbell et al.

    Prediction of heart failure by amino terminal-pro-B-type natriuretic peptide and C-reactive protein in subjects with cerebrovascular disease

    Hypertension

    (2005)
  • C. Ishikawa et al.

    Prediction of mortality by high-sensitivity C-reactive protein and brain natriuretic peptide in patients with dilated cardiomyopathy

    Circ J

    (2006)
  • A. Khera et al.

    Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study

    Circulation

    (2006)
  • Y. Nishio et al.

    Cardiac troponin T vs other biochemical markers in patients with congestive heart failure

    Circ J

    (2007)
  • J. Danesh et al.

    C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease

    N Engl J Med

    (2004)
  • M.P. Bonaca et al.

    Defining a role for novel biomarkers in acute coronary syndromes

    Clin Chem

    (2008)
  • Cited by (49)

    • Protective effect of Vernonia amygdalina Delile against doxorubicin-induced cardiotoxicity

      2021, Heliyon
      Citation Excerpt :

      Clinically, the left ventricular ejection fraction (LVEF) provides a marker that can be reliably applied to patients for guidelines on medical therapy. Research and development of heart failure biomarkers, such as BNP, CK-MB, troponin T, and LDH, has undergone rapid growth [8, 9]. Until now, the guidelines for preventive therapy for cardiotoxicity due to doxorubicin have not yet been available; therefore, it is essential to research compounds that can be used as cardioprotective agents for doxorubicin therapy.

    • A sandwich-type photoelectrochemical immunosensor for NT-pro BNP detection based on F-Bi <inf>2</inf> WO <inf>6</inf> /Ag <inf>2</inf> S and GO/PDA for signal amplification

      2019, Biosensors and Bioelectronics
      Citation Excerpt :

      Heart failure has been known as a disease in which the ability of heart is insufficient to meet the body's blood circulation need (Liquori et al., 2014; Tian et al., 2014).

    • Glucotoxicity results in apoptosis in H9c2 cells via alteration in redox homeostasis linked mitochondrial dynamics and polyol pathway and possible reversal with cinnamic acid

      2018, Toxicology in Vitro
      Citation Excerpt :

      The diminished endogenous antioxidant defense mechanisms like superoxide dismutase (SOD), catalase, and glutathione peroxidase or reduced concentrations of endogenous antioxidants like vitamin E, ascorbic acid, and glutathione (GSH) can increase the ROS levels (Kayama et al., 2015). In response to injury, cardiomyocytes release certain biomarkers such as the natriuretic peptides {atrial natriuretic peptide (ANP) and brain natriuretic peptide}, creatine kinase (Liquori et al., 2014), lactate dehydrogenase (LDH) (Bodor, 2016) etc. These biomarkers are very important as they can be used to monitor heart function.

    View all citing articles on Scopus
    View full text